Thursday, 15 October 2026European Markets

COVIVIO HOTELS, CBO TERRITORIA, Another 2 Companies Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - covivio hotels (covh.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
covivio hotels (covh.pa) €16.35 7.67% 5.55%
cbo territoria (cbot.pa) €3.68 6.54% 7.61%
immo moury (immou.br) €34.00 5.14% 9.04%
ctp (ctpnv.as) €15.32 3.26% 16.95%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. covivio hotels (covh.pa)

7.67% forward dividend yield and 5.55% return on equity

covivio hotels specializes in owning business premises in the hotel sector. a listed real estate investment company (siic), a real estate partner of the major players in the hotel industry, covivio hotels holds assets worth eur 6.6 billion (at end 2022). covivio hotels is graded bbb+ / stable outlook by standard and poor's.

earnings per share

as for profitability, covivio hotels has a trailing twelve months eps of €3.23.

pe ratio

covivio hotels has a trailing twelve months price to earnings ratio of 5.06. meaning, the purchaser of the share is investing €5.06 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.55%.

dividend yield

according to morningstar, inc., the next dividend payment is on apr 21, 2023, the estimated forward annual dividend rate is 1.25 and the estimated forward annual dividend yield is 7.67%.

yearly top and bottom value

covivio hotels's stock is valued at €16.35 at 01:30 est, way under its 52-week high of €18.30 and way above its 52-week low of €14.50.

volatility

covivio hotels's last week, last month's, and last quarter's current intraday variation average was a positive 0.31%, a negative 0.05%, and a positive 0.82%.

covivio hotels's highest amplitude of average volatility was 0.92% (last week), 0.56% (last month), and 0.82% (last quarter).

more news about covivio hotels.

2. cbo territoria (cbot.pa)

6.54% forward dividend yield and 7.61% return on equity

cbo territoria sa engages in the urban planning and development, and property development and investment activities in france. the company develops and sells housings, retail parks, offices, industrial premises, shops, plots of land, business premises, and warehouses. it is also involved in the leisure, catering, marketing, and coworking businesses. cbo territoria sa was incorporated in 2004 and is headquartered in sainte-marie, france.

earnings per share

as for profitability, cbo territoria has a trailing twelve months eps of €0.43.

pe ratio

cbo territoria has a trailing twelve months price to earnings ratio of 8.56. meaning, the purchaser of the share is investing €8.56 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.61%.

yearly top and bottom value

cbo territoria's stock is valued at €3.68 at 01:30 est, under its 52-week high of €3.93 and above its 52-week low of €3.48.

moving average

cbo territoria's value is higher than its 50-day moving average of €3.63 and higher than its 200-day moving average of €3.65.

revenue growth

year-on-year quarterly revenue growth grew by 25.2%, now sitting on 90.75m for the twelve trailing months.

more news about cbo territoria.

3. immo moury (immou.br)

5.14% forward dividend yield and 9.04% return on equity

immo moury sca is a real estate investment trust. immo moury sca is based in belgium.

earnings per share

as for profitability, immo moury has a trailing twelve months eps of €2.52.

pe ratio

immo moury has a trailing twelve months price to earnings ratio of 13.49. meaning, the purchaser of the share is investing €13.49 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.04%.

yearly top and bottom value

immo moury's stock is valued at €34.00 at 01:30 est, way under its 52-week high of €41.00 and above its 52-week low of €31.60.

more news about immo moury.

4. ctp (ctpnv.as)

3.26% forward dividend yield and 16.95% return on equity

ctp n.v. owns, develops, manages, and leases logistics and industrial real estate properties in central, western, and eastern europe. the company offers various building for small and growing businesses, global enterprises, built to suit, and other offices. it also develops urban parks which are harbour mixed-use building and space types, such as premium offices, retail stores, office services, public spaces, and other amenities. ctp n.v. was founded in 1998 and is based in amsterdam, the netherlands. ctp n.v. (enxtam:ctpnv) operates as a subsidiary of ctp holding b.v.

earnings per share

as for profitability, ctp has a trailing twelve months eps of €2.08.

pe ratio

ctp has a trailing twelve months price to earnings ratio of 7.37. meaning, the purchaser of the share is investing €7.37 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.95%.

more news about ctp.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com